PDF Cover

Inhaled Insulin Market

The market for Inhaled Insulin was estimated at $463 million in 2025; it is anticipated to increase to $715 million by 2030, with projections indicating growth to around $1.11 billion by 2035.

Report ID:DS1801244
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Inhaled Insulin
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Inhaled Insulin Market Outlook

Revenue, 2025

$463M

Forecast, 2035

$1.11B

CAGR, 2026 - 2035

9.1%

The Inhaled Insulin industry revenue is expected to be around $504.8 million in 2026 and expected to showcase growth with 9.1% CAGR between 2026 and 2035. This anticipated expansion reflects the rising importance of patient-friendly diabetes therapies as healthcare systems increasingly prioritize treatment adherence and quality of life. Inhaled insulin is gaining recognition as a convenient alternative to injectable insulin, particularly for patients who experience injection fatigue or needle anxiety. The growing global prevalence of diabetes, combined with the need for rapid-acting glycemic control solutions, is encouraging healthcare providers to consider inhaled formulations as part of comprehensive diabetes management strategies. Improvements in pulmonary drug-delivery technologies and the development of compact inhaler devices have further strengthened the commercial viability of inhaled insulin. In addition, expanding awareness among endocrinologists and patients regarding non-invasive insulin delivery is supporting wider adoption. Regulatory approvals in key markets and strategic partnerships between pharmaceutical companies and device developers are also contributing to the strengthening position of inhaled insulin within the broader diabetes therapeutics landscape.

Inhaled insulin is a rapid-acting insulin formulation delivered through specialized inhaler devices that enable absorption through the lungs into the bloodstream. It is primarily used to control postprandial blood glucose levels in individuals with diabetes, particularly in patients with type 1 diabetes who require mealtime insulin and in certain type 2 diabetes patients needing additional glycemic control alongside long-acting basal insulin. One of its key features is its fast onset of action, which more closely mimics the body’s natural insulin response during meals compared with many injectable options. The therapy is typically administered through dry powder inhalers designed to provide precise dosing and convenient use. Major applications lie in outpatient diabetes management and personalized treatment regimens. Recent trends influencing demand include the development of next-generation inhalation devices, increased emphasis on patient-centric therapies, and growing clinical research aimed at improving dosing accuracy and pulmonary safety profiles.

Inhaled Insulin market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Inhaled Insulin Market Outlook

Market Key Insights

  • The Inhaled Insulin market is projected to grow from $462.7 million in 2025 to $1.11 billion in 2035. This represents a CAGR of 9.1%, reflecting rising demand across Diabetes Management, Sports Nutrition, and Clinical Trials for Cognitive Disorders.

  • MannKind is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and UK are the top markets within the Inhaled Insulin market and are expected to observe the growth CAGR of 6.6% to 9.6% between 2025 and 2030.

  • Emerging markets including Brazil, South Africa and Saudi Arabia are expected to observe highest growth with CAGR ranging between 8.7% to 11.4%.

  • Slow adoption of Transition Toward Patient Centric and Non Invasive Diabetes Treatment Approaches transition within key players in Inhaled Insulin market is creating a revenue window for adjacent and alternate markets like Oral Insulin Pills and Transdermal Insulin Patches to improve its use-case penetration in Hospitals and Home Care applications and expected to capture $33 million revenue from existing Inhaled Insulin market.

  • The Inhaled Insulin market is set to add $643 million between 2025 and 2035, with manufacturer targeting Home Care & Speciality Clinics Application projected to gain a larger market share.

  • With

    rising prevalence of diabetes, and

    Technological Advancements in Drug Administration, Inhaled Insulin market to expand 139% between 2025 and 2035.

inhaled insulin market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Inhaled Insulin - Country Share Analysis

Opportunities in the Inhaled Insulin

Another promising opportunity is also emerging from clinical research exploring inhalation based insulin therapies for neurological disorders. Researchers are investigating intranasal or inhalation delivered insulin as a potential treatment for cognitive disorders such as Alzheimer’s disease and mild cognitive impairment. In these studies, low dose inhaled insulin is evaluated for its ability to influence brain insulin signaling pathways associated with memory and cognitive function. This research trend could open a new therapeutic segment beyond traditional diabetes treatment. Academic institutions and biotechnology companies are increasingly collaborating on early stage clinical trials, and future success in this area could significantly expand the application scope and long term market potential of inhaled insulin technologies.

Growth Opportunities in North America and Asia Pacific

North America represents a leading regional market for inhaled insulin, supported by advanced diabetes care infrastructure, strong pharmaceutical innovation, and high awareness of alternative insulin delivery systems. The region benefits from a large population living with type 1 and type 2 diabetes, which continues to create demand for rapid acting insulin therapies that improve treatment adherence. A key driver in this market is the growing preference for non invasive insulin delivery solutions that reduce injection related discomfort while supporting effective postprandial glucose control. The United States remains the primary commercialization hub, where companies such as MannKind Corporation actively promote inhaled insulin products through endocrinology networks and diabetes clinics. Opportunities are emerging through integration with digital diabetes management tools and patient monitoring platforms that enhance therapy adherence. Competition is moderate but evolving, as pharmaceutical companies, device developers, and digital health firms collaborate to create comprehensive diabetes management ecosystems. Continued regulatory support and ongoing clinical research are expected to strengthen market adoption across North America.
Asia Pacific is emerging as a high growth region for the inhaled insulin market due to rapidly increasing diabetes prevalence and expanding access to modern diabetes therapies. Countries such as China, India, and Japan are witnessing rising demand for innovative insulin delivery methods as healthcare systems focus on improving long term diabetes management outcomes. A major driver in this region is the growing middle class population and increasing healthcare spending, which is enabling greater adoption of advanced treatment options. Market opportunities are particularly strong in urban healthcare centers where physicians are more familiar with rapid acting inhaled insulin therapies. Recent product launches and distribution partnerships are helping to introduce inhaled insulin into regional markets. Competition is gradually intensifying as multinational pharmaceutical companies collaborate with local distributors to expand market reach. In addition, government initiatives aimed at improving diabetes diagnosis and treatment accessibility are expected to further stimulate demand for alternative insulin delivery technologies.

Market Dynamics and Supply Chain

01

Driver: Rising Global Diabetes Prevalence and Growing Patient Preference for Non Invasive Insulin Delivery

The increasing prevalence of diabetes worldwide continues to create strong demand for more convenient and patient friendly insulin delivery methods. Rising rates of type 1 and type 2 diabetes, particularly in aging populations and rapidly urbanizing regions, are also expanding the pool of patients requiring long term insulin therapy. As treatment duration increases, many patients experience challenges related to injection fatigue, needle anxiety, and adherence to multiple daily injections. These concerns are also encouraging healthcare providers to explore alternative insulin delivery technologies that improve patient comfort and compliance. Inhaled insulin has also emerged as a promising option because it eliminates the need for mealtime injections while maintaining rapid glucose lowering capability. At the same time, improvements in dry powder insulin formulations and pulmonary drug delivery technologies have also enhanced dosing precision and safety. Modern inhaler devices are also designed to provide consistent particle distribution and efficient lung absorption, allowing rapid acting insulin to reach systemic circulation quickly. These technological advancements are also helping position inhaled insulin as a practical complementary therapy within modern diabetes management strategies.
Continuous innovation in pulmonary drug delivery technology is also playing a significant role in advancing the inhaled insulin market. Pharmaceutical companies and medical device manufacturers are also investing in next generation inhaler systems designed to improve insulin particle stability, absorption efficiency, and dosing reliability. Modern dry powder inhalers utilize advanced particle engineering techniques that optimize insulin particle size for deep lung deposition, which enhances bioavailability and enables rapid systemic uptake. These developments are also addressing earlier challenges related to inconsistent absorption and variability in dosing that historically limited adoption of inhaled insulin therapies. In addition, improved inhaler ergonomics and digital dose monitoring technologies are also supporting better treatment adherence and clinical oversight. Some devices now incorporate breath activated mechanisms and compact cartridge systems that simplify administration for patients. As these technological improvements continue to enhance performance and patient usability, inhaled insulin is also becoming a more viable therapeutic option within the broader insulin delivery landscape.
02

Restraint: Concerns Over Pulmonary Safety and Restricted Use Among Patients With Respiratory Conditions

One of the most significant restraints limiting the adoption of inhaled insulin is the continued concern regarding pulmonary safety and its restricted eligibility for patients with respiratory conditions. Since inhaled insulin is absorbed through the lungs, healthcare providers must carefully screen patients for lung diseases such as asthma or chronic obstructive pulmonary disease before prescribing the therapy. This requirement often involves spirometry testing and periodic lung function monitoring, which increases treatment complexity and discourages routine prescribing. In addition, mild side effects such as cough and small changes in lung function have been reported in clinical studies, leading to cautious adoption among clinicians. These concerns directly influence market revenue by restricting the eligible patient population and slowing prescription rates despite growing diabetes prevalence.
03

Opportunity: Expanding Type 2 Diabetes Patient Population Seeking Needle Free Insulin Therapies and Adoption of Advanced Compact Dry Powder Inhalers In Diabetes Care

A major opportunity in the inhaled insulin market lies in the growing number of type 2 diabetes patients who require prandial insulin but prefer alternatives to multiple daily injections. Many patients delay insulin initiation due to fear of needles or concerns about injection related inconvenience. Rapid acting dry powder inhaled insulin offers a practical solution for these patients by providing mealtime glucose control without injection based administration. Healthcare providers are increasingly exploring inhaled insulin as an adjunct to basal insulin therapy in type 2 diabetes management. Demand is expected to grow particularly in outpatient diabetes care settings across North America and Europe, where patient centric treatment approaches and adherence focused therapies are gaining strong attention.
Technological advancements in compact inhaler devices are creating new opportunities for inhaled insulin adoption in diabetes care. Modern dry powder inhalers are designed with improved particle engineering and breath activated delivery mechanisms that enable precise dosing and consistent pulmonary absorption. These devices are becoming smaller, easier to use, and more portable, which enhances patient convenience and treatment adherence. Manufacturers are also integrating digital monitoring features that allow physicians to track dosage patterns and patient compliance. These technological innovations are expected to drive demand for next generation rapid acting inhaled insulin products. Growth is anticipated in technologically advanced healthcare markets where digital health integration and connected drug delivery devices are becoming increasingly common.
04

Challenge: High Treatment Costs and Historical Commercial Failures Limiting Physician and Payer Confidence

High therapy costs and past commercial setbacks continue to influence demand patterns in the inhaled insulin market. Compared with traditional injectable insulin, inhaled insulin therapies typically involve higher expenses due to specialized inhaler devices, proprietary insulin formulations, and additional clinical monitoring requirements. These higher costs can discourage both patients and healthcare payers, particularly in price sensitive healthcare systems and developing markets. Furthermore, the historical withdrawal of early inhaled insulin products such as Exubera due to weak sales created lingering skepticism among physicians and investors about the commercial sustainability of this therapy category. This historical context continues to affect reimbursement decisions, marketing investment, and physician prescribing behavior, ultimately slowing broader market expansion and limiting revenue growth in the segment.

Supply Chain Landscape

1

API Manufacturing

Novo Nordisk A/SEli Lilly and CompanyBiocon Limited
2

Drug Formulation

MannKind CorporationCipla Limited
3

Inhaler Devices

Phillips-MedisizeAptarGroup Inc.Gerresheimer AG
4

End-Use Applications

Diabetes ManagementClinical Research ApplicationsHospital Diabetes Care
Inhaled Insulin - Supply Chain

Use Cases of Inhaled Insulin in Diabetes Management & Clinical Trials for Cognitive Disorders

Diabetes Management : Diabetes management represents the primary application of inhaled insulin, particularly for patients requiring rapid prandial glucose control. In this segment, rapid acting dry powder inhaled insulin formulations are most commonly used, as they are designed to be administered at the beginning of meals to regulate postprandial blood glucose levels. These formulations are delivered through compact inhaler devices that allow insulin to be absorbed through the lungs into the bloodstream within minutes. The main end users include patients with type 1 diabetes and selected patients with type 2 diabetes who require mealtime insulin in combination with basal insulin therapy. The key advantage of inhaled insulin in diabetes management lies in its non invasive administration, which improves treatment adherence and patient comfort. In addition, its fast onset and relatively short duration of action closely resemble physiological insulin release during meals, supporting more flexible dosing and effective glycemic control in outpatient diabetes care settings.
Sports Nutrition : In the sports nutrition sector, inhaled insulin is being explored in limited and controlled contexts to understand its role in enhancing nutrient uptake and metabolic efficiency during recovery periods. Rapid acting inhaled insulin formulations are typically evaluated in research environments involving athletes or metabolically active individuals. The principle behind this application relates to insulin’s ability to facilitate glucose transport into muscle cells and stimulate glycogen synthesis following intense physical activity. Inhaled delivery offers a fast acting response that can theoretically support quicker carbohydrate utilization compared with slower acting injectable forms. Although this application remains highly specialized and not widely commercialized, research interest continues because of the potential metabolic benefits associated with optimized glucose handling and improved post exercise recovery. Regulatory oversight and medical supervision are essential in this context to ensure safe use and appropriate metabolic monitoring.
Clinical Trials for Cognitive Disorders : Clinical trials investigating cognitive disorders represent an emerging research application for inhaled insulin. In these studies, specially formulated intranasal or inhalation based insulin delivery systems are explored for their potential neurological effects rather than glycemic control. Researchers are examining how small doses of inhaled insulin may influence brain insulin signaling pathways that are associated with memory, learning, and neuroprotection. Early stage clinical research has focused on neurodegenerative conditions such as Alzheimer’s disease and mild cognitive impairment, where altered insulin signaling in the brain has been observed. Inhalation based delivery offers a non invasive approach that may allow insulin to influence central nervous system activity without significantly affecting systemic blood glucose levels. This area remains experimental, but ongoing clinical investigations are generating interest in the broader therapeutic potential of inhaled insulin beyond traditional diabetes treatment.

Recent Developments

Recent developments in the inhaled insulin market highlight expanding commercialization and clinical validation of rapid-acting inhaled insulin therapies. Regulatory approval and market launch of inhaled insulin products such as Afrezza in emerging markets like India, supported through partnerships between pharmaceutical companies and regional distributors, is improving global accessibility and strengthening the pulmonary drug delivery segment. Clinical studies are also reinforcing its value in diabetes management, showing comparable glycemic control to traditional injections while improving patient satisfaction. A key market trend is the growing focus on needle-free insulin delivery systems, encouraging investment in next-generation inhaler devices and expanding adoption across outpatient diabetes care.

February 2026 : MannKind Corporation reported strong commercialization progress for its inhaled insulin product Afrezza, alongside strategic expansion initiatives including the acquisition of scPharmaceuticals and updates on pipeline programs, strengthening its cardiometabolic therapy portfolio and revenue growth trajectory.
January 2026 : MannKind Corporation received U.S. FDA approval for an updated label for Afrezza inhaled insulin that provides improved starting-dose guidance for patients switching from multiple daily injections or insulin pump therapy, supporting broader clinical adoption in diabetes management.

Impact of Industry Transitions on the Inhaled Insulin Market

As a core segment of the Medical Device industry, the Inhaled Insulin market develops in line with broader industry shifts. Over recent years, transitions such as Transition Toward Patient Centric and Non Invasive Diabetes Treatment Approaches and Shift From Single Therapy Solutions Toward Integrated Diabetes Management Platforms have redefined priorities across the Medical Device sector, influencing how the Inhaled Insulin market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition Toward Patient Centric and Non Invasive Diabetes Treatment Approaches

The inhaled insulin industry is experiencing a transition toward patient centric diabetes care that prioritizes convenience, adherence, and quality of life. Traditional insulin delivery methods relied heavily on multiple daily injections, but healthcare providers and pharmaceutical companies are increasingly focusing on non invasive alternatives such as inhaled insulin therapies. This shift is encouraging innovation in compact inhaler devices and rapid acting insulin formulations designed for mealtime glucose control. The transition is also influencing the broader medical device and digital health industries, where companies are developing connected inhaler systems and adherence monitoring tools. As patient experience becomes a key differentiator, healthcare providers and insurers are increasingly evaluating therapies that support long term treatment compliance.
02

Shift From Single Therapy Solutions Toward Integrated Diabetes Management Platforms

Another important transition is the movement from standalone insulin therapies toward integrated diabetes management ecosystems. Inhaled insulin is increasingly being positioned as part of a broader treatment strategy that combines continuous glucose monitoring, basal insulin therapy, and digital health platforms. This trend is encouraging collaborations between pharmaceutical companies, device manufacturers, and digital health providers to create coordinated treatment solutions. For example, inhaled insulin providers are exploring partnerships with companies developing glucose monitoring technologies and mobile health applications that help patients track insulin usage and glycemic patterns. This transition is influencing both the diabetes therapeutics market and the digital healthcare sector, where integrated treatment models are becoming central to personalized chronic disease management.